Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
Développer la qualité dans le champ sanitaire, social et médico-social
Logo
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. OXIS TURBUHALER (formotérol)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • Établissements de santé
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

OXIS TURBUHALER (formotérol)

Medicine - Posted on Feb 02 2010 - Updated on Jun 12 2019
Active substance (DCI)
  • formotérol
history (4)
  • 1/13/10

    OXIS TURBUHALER (formotérol)

    OXIS TURBUHALER (formotérol)
    icône flèche
  • 9/6/06

    OXIS TURBUHALER (formotérol)

    OXIS TURBUHALER (formotérol)
    icône flèche
  • 7/6/05

    OXIS TURBUHALER 12 microgrammes/dose, poudre pour inhalation (Boîte de 60 doses (code CIP : 363 518-2))

    OXIS TURBUHALER 12 microgrammes/dose, poudre pour inhalation (Boîte de 60 doses (code CIP : 363 518-2))
    icône flèche
  • 9/15/04

    OXIS TURBUHALER 12 µg PAR DOSE, poudre pour inhalation - 60 doses (formotérol)

    OXIS TURBUHALER 12 µg PAR DOSE, poudre pour inhalation - 60 doses (formotérol)
    icône flèche
Technical information
ATC code
  • R03AC13
Manufacturer
Laboratoire ASTRAZENECA
Presentation

OXIS TURBUHALER 12 µg/dose, poudre pour inhalation Boîte de 60 doses - Code CIP : 3635182

All our publications
    Bronchial diseases Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
rtGUn2YNJCusEQ7q